The Treatment of the Rubeosis of the Iris and the Neovascular Glaucoma in Proliferative Diabetic Retinopathy by Means of anti-VEGF
Authors:
M. Černák; O. Markovic; A. Černák
Authors place of work:
Očná klinika FNsP a SZU, Bratislava, prednosta prof. MUDr. Andrej Černák, DrSc.
; AKH Linz, prednosta priv. doc. Sigfrit Priglinger
Published in the journal:
Čes. a slov. Oftal., 64, 2008, No. 6, p. 234-236
Summary
The rubeosis of the iris is a serious complication especially in diabetic retinopathy and retinal veins occlusion. Cytokines, especially the vascular growing factor (VEGF), are responsible for the forming of new vessels. The treatment that inhibits the effect of the VEGF presents new possibilities in the neovascular diseases treatment. Bevacizumab (Avastin) is an anti-VEGF antibody that blocks all forms of VEGF-A. In three eyes with proliferative diabetic retinopathy and neovascularization of the iris and the anterior chamber angle, the dose of 1.25 mg of Avastin was applied intravitrealy. Just one week after the application of the drug, the decrease of the leakage on the iris, and the total disappearance of the neovascularization in three weeks were visible on the fluorescein angiogram. The recurrence of the neovascularization was found in one eye after three months and the treatment had to be repeated. Nine months after the second application, the disease is stabilized without the neovascularization. The intraocular pressure was elevated in two eyes before the application of Avastin, and was refractive to the treatment. After the disappearance of the neovascularization, the intraocular pressure was normalized and it was possible to terminate the antiglaucomatous therapy. The bevacizumab intravitreal treatment of the neovascularization of the iris and the anterior chamber angle was proved to be efficient, the neovascularization disappeared and the intraocular pressure was normalized. There were no side effects after the bevacizumab applications in any of our patients.
Key words:
Bevacizumab, Avastin, proliferative diabetic retinopathy, neovascular glaucoma, rubeosis of the iris
Zdroje
1. Avery, RL.: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment, Retina, 26, 2006, 3: 352-354
2. Avery, RL., Pearlman, J., Pieramici, DJ. et al.: Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy, Ophthalmology, 113, 2006, 10:1695.e1-15.
3. Barile, GR., Chang, S., Horowitz, JD. et al.: Neovascular complications associated with rubeosis iridis and peripheral retinal detachment after retinal detachment surgery, Am J Ophthalmol, 126, 1998, 3: 379-389
4. Chilov, MN., Grigg, JR., Playfair, TJ.: Bevacizumab (Avastin) for the treatment of neovascular glaucoma, Clin Experiment Ophthalmol., 35, 2007 Jul, 5: 494-506.
5. Davidorf, FH., Mouser, JG., Derick, RJ.: Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection, Retina, 26, 2006 Mar, 3: 354-356
6. Grisanti, S., Biester, S., Peters, S., Tatar, O. et al.: Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis, Am J Ophthalmol., 142, 2006 Jul, 1:158-160
7. Iliev, ME., Domig, D., Wolf-Schnurrbursch, U. et al.: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma, Am J Ophthalmol.,142, 2006 Dec, 6: 1054-1056
8. Iturralde, D., Spaide, RF., Meyerle, CB., Klancnik, JM. et al.: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study, Retina, 26, 2006 Mar, 3: 279- 284
9. Kahook, MY., Schuman, JS., Noecker, RJ.: Intravitreal bevacizumab in a patient with neovascular glaucoma, Ophthalmic Surg Lasers Imaging, 37, 2006 Mar-Apr, 2: 144-146
10. Mason, JO., Albert, MA. Jr., Mays, A. et al.: Regression of neovascular iris vessels by intravitreal injection of bevacizumab, Retina, 26, 2006 Sep, 7: 839-841
11. Silva Paula, J., Jorge, R., Alves Costa, R. et al.: Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma, Acta Ophthalmol Scand., 84, 2006 Aug, 4: 556-557
12. Tolentino, MJ., Miller, JW., Gragoudas, ES. et al.: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate, Arch Ophthalmol., 114, 1996 Aug, 8: 964-970
13. Vatavuk, Z., Bencic, G., Mandic, Z.: Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion, Eur J Ophthalmol., 17, 2007 Mar-Apr, 2: 269-271
14. Yazdani, S., Hendi, K., Pakravan, M.: Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma, J Glaucoma, 16, 2007 Aug, 5: 437-439
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2008 Číslo 6
Najčítanejšie v tomto čísle
- Orbital Tumors in Adults – a Decennary Study
- Intraoperative Floppy Iris Syndrome versus Lens-Iris Diaphragm Retropulsion Syndrome
- The Treatment of the Rubeosis of the Iris and the Neovascular Glaucoma in Proliferative Diabetic Retinopathy by Means of anti-VEGF
- Thrombolysis in Central Retinal Artery Occlusion using the Alteplasis